Show simple item record

Files in this item


Item metadata

dc.contributor.authorSullivan, Francis
dc.contributor.authorTello, Agnes
dc.contributor.authorRauchhaus, Petra
dc.contributor.authorHernandez Santiago, Virginia
dc.contributor.authorDaly, Fergus
dc.identifier.citationSullivan , F , Tello , A , Rauchhaus , P , Hernandez Santiago , V & Daly , F 2022 , ' Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection ' , Journal of Circulating Biomarkers , vol. 11 , pp. 24-27 .
dc.identifier.otherPURE: 279431495
dc.identifier.otherPURE UUID: 4035592b-672e-436e-b7cf-e0fa9d305299
dc.identifier.otherORCID: /0000-0002-6623-4964/work/112711497
dc.identifier.otherORCID: /0000-0002-8544-1483/work/112711515
dc.identifier.otherScopus: 85130482767
dc.descriptionThis project was funded by The Lung Foundation.en
dc.description.abstractBackground : Patients with more severe forms of SARS-CoV-2 exhibit activation of immunological cascades. Participants (current or ex-smokers with at least 20 years pack history) in a trial (Early Diagnosis of Lung Cancer, Scotland [ECLS]) of autoantibody detection to predict lung cancer risk had seven autoantibodies measured 5 years before the pandemic. This study compared the response to Covid infection in study participants who tested positive and negative to antibodies to tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2. Methods : Autoantibody data from the ECLS study was deterministically linked to the EAVE II database, a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of SARS-CoV-2 infection, patterns of healthcare use and outcomes. The strength of associations was explored using a network algorithm for exact contingency table significance testing by permutation. Results : There were no significant differences discerned between SARS-CoV-2 test results and EarlyCDT-Lung test results (p = 0.734). An additional analysis of intensive care unit (ICU) admissions detected no significant differences between those who tested positive and negative. Subgroup analyses showed no difference in COVID-19 positivity or death rates amongst those diagnosed with chronic obstructive pulmonary disease (COPD) with positive and negative EarlyCDT results. Conclusions : This hypothesis-generating study demonstrated no clinically valuable or statistically significant associations between EarlyCDT positivity in 2013-15 and the likelihood of SARS-CoV-2 positivity in 2020, ICU admission or death in all participants (current or ex-smokers with at least 20 years pack history) or in those with COPD or lung cancer.
dc.relation.ispartofJournal of Circulating Biomarkersen
dc.rightsCopyright © 2022 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial use is not permitted and is subject to Publisher’s permissionsen
dc.subjectCurrent or ex-smokersen
dc.subjectLung canceren
dc.subjectMortality predictionen
dc.subjectSerum biomarkersen
dc.subjectQR180 Immunologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleAssessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infectionen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews. Population and Behavioural Science Divisionen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record